Mendus – executive interview

In this video, we speak with Dr Leopold Bertea, CTO at Mendus, focusing primarily on cell therapy manufacturing. We discuss key considerations for biotech and pharma companies consider when planning manufacturing, the significance of vididencel as an off-the-shelf therapy and Mendus’s crucial manufacturing alliance with NorthX Biologics. We also highlight key manufacturing milestones that investors should be aware of over the next 12–18 months.

Mendus is a Sweden-based immuno-oncology company specialising in allogeneic dendritic cell biology. Its leading clinical candidate is vididencel, an off-the-shelf, cell-based cancer vaccine, which is being evaluated in clinical trials as a potential maintenance treatment for acute myeloid leukaemia (AML, the lead programme) and ovarian cancer. In AML, vididencel has shown clinical proof-of-concept as a single-agent maintenance therapy in the ADVANCE II trial, and it is currently being evaluated in the Phase II CADENCE trial (sponsored and conducted by the Australasian Leukaemia and Lymphoma Group) in combination with Onureg. In parallel, Mendus is preparing for the pivotal stages of development and is on track to be pivotal-stage ready from H225. A key component of this is the company’s manufacturing capabilities.